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Purpose: To study the clinical characteristics of optic neuritis in Korean children.
Methods: A retrospective review of the medical charts of 20 patients who were diagnosed with optic neuritis before 
age 10 was conducted in this study. Data were collected on the demographics, clinical features, use of intra-
venous corticosteroids, neuroimaging, and diagnosis of multiple sclerosis. 
Results: The mean age at diagnosis was 6.5 ± 1.8 years (range, 3 to 9 years). Seventeen patients (85%) were fe-
male, and 13 patients (65%) exhibited bilateral diseases. Visual acuity had decreased to ≤20 / 200 in 16 of the 20 
patients, and recovered to ≥20 / 40 in 16 of the 20 patients. The mean duration between the worst visual acuity 
and 20 / 40 was 2.30 ± 2.91 months. Intravenous corticosteroid treatment was performed in 15 patients and ex-
erted a beneficial effect on the visual outcomes. Disc swelling was observed in 75.8% of the affected eyes. 
Multiple sclerosis was diagnosed in five patients with a mean follow-up period of 21.9 ± 20.3 months. The pres-
ence of lesions in brain magnetic resonance images was identified as the most significant factor with regards to 
the occurrence of multiple sclerosis. 
Conclusions: In children with optic neuritis, a profound decrease in initial visual acuity and rapid recovery of visual 
acuity were confirmed. Corticosteroid treatment resulted in a beneficial effect on visual outcomes, but had no ef-
fect on the risk of multiple sclerosis.
Key Words: Corticosteroid, Multiple sclerosis, Optic neuritis 
ⓒ2011 The Korean Ophthalmological Society
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses
/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Received: June 14, 2010    Accepted: July 27, 2010
Corresponding Author: Seong-Joon Kim, MD. Department of Ophthalmology,
Seoul National University College of Medicine, #28 Yeongeon-dong, 
Jongno-gu, Seoul 110-744, Korea. Tel: 82-2-2072-1979, Fax: 82-2-741-3187, 
Email: ophjun@snu.ac.kr
Anterior and bilateral types of optic neuritis are more com-
mon in children than adults [1]. Many cases have been re-
ported to have occurred within one or two weeks after viral 
infection or vaccination [2-4]. The relationship between op-
tic neuritis and multiple sclerosis (MS) has been well-estab-
lished, and several articles have noted a lower incidence of 
MS in children with optic neuritis [3,5-11]. Since there have 
been no studies of childhood optic neuritis comparable to the 
Optic Neuritis Treatment Trial (ONTT), a multi-center, 
randomized, placebo-controlled trial for adult optic neuritis, 
the previous results regarding childhood optic neuritis cannot 
be viewed as complete or definitive.  
In previous studies on childhood optic neuritis, the study 
populations were heterogeneous in nature, owing to the broad 
age distributions of the subject children. Some previous re-
ports have suggested that hormonal effects and puberty af-
fected the clinical manifestations of the condition [4,6,12]. 
Working from this perspective, several authors have focused 
on prepubertal patients, however, the number of study pa-
tients was small [12,13]. 
In this study, we describe the clinical characteristics of op-
tic neuritis in young children who were diagnosed before the 
age of 10. This age group was chosen in order to exclude 
postpubertal adolescents who might exhibit characteristics of 
adulthood. 
Materials and Methods 
Our study reviewed patients younger than 10 years of age DH Jo, et al. Optic Neuritis in Korean Children
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Table 1. Demographic findings and treatment options of the study patients
No. Age (yr) Sex  Laterality  Presence of 
visual recovery
Development of 
multiple sclerosis
Intravenous corticosteroid 
treatment
13 F B Y N Y
27 F B Y N Y
37 F U Y N Y
47 F B N Y N
59 F U Y N Y
69 M B Y N Y
76 F B Y Y Y
89 F B N N N
98 F U Y N Y
10 5 F U N N N
11 5 M B Y Y N
12 6 F B Y N N
13 6 F B N N Y
14 5 F B Y Y Y
15 6 F B Y N Y
16 9 F U Y Y Y
17 7 F U Y N Y
18 6 M U Y N Y
19 5 F B Y N Y
20 4 F B Y N Y
Age = age at diagnosis; F = female; M = male; B = bilateral; U = unilateral; Y = yes; N = no.
that visited the Seoul National University Children’s 
Hospital and were diagnosed with optic neuritis between 
November 1st, 1996 and October 31st, 2008. Optic neuritis 
was diagnosed on the basis of the following clinical symp-
toms and signs: acute loss of visual acuity or visual field last-
ing 8 days or less, relative afferent pupillary defect, and ab-
normal color vision. Additionally, bilateral disease was de-
fined as a loss of vision in the other eye occurring within two 
weeks after the initial attack. All cases were confirmed by an 
experienced neuro-ophthalmologist (SJK).
Patients who had a history of corticosteroid treatment, neu-
rological disorders at the initial examination, and other ocu-
lar or systemic diseases were excluded. Among the patients 
who fulfilled these criteria, 6 patients were excluded for the 
following exclusion criteria: 1 for a previous history of ste-
roid treatment to treat suspicious optic neuritis, 2 for diag-
nosis of neuromyelitis optica, and 3 for too brief of a fol-
low-up period (less than 6 months). After these exclusions, 
20 patients were identified for our study.    
The following data were recorded: demographics (age at 
diagnosis, sex), clinical profiles (laterality, initial visual acui-
ty, worst visual acuity, final visual acuity, duration between 
initial symptom and recovery), ophthalmologic character-
istics (disc swelling, visual evoked potential, results of color 
vision test and visual field test), presumed or definite viral in-
fection or vaccination preceding visual loss, findings in brain 
magnetic resonance images (MRI), development of MS, and 
the use of steroid treatment. We considered 20 / 40 as func-
tionally good visual acuity, and the duration of visual recov-
ery to 20 / 40 was checked. Diagnosis of clinically definite 
MS was confirmed by an experienced pediatric neurologist 
(JHC) on the basis of the criteria developed by McDonald et 
al. [14] and revised by Polman et al. [15].
For the statistical analysis for visual outcomes and the risk 
of MS according to the use of corticosteroid treatment and 
other clinical features, the Mann-Whitney U-test and the 
crossover tabulation test were conducted, respectively. We 
used SPSS ver. 17.0 (SPSS Inc., Chicago, IL, USA) for the 
analysis, and regarded the result as statistically significant 
when the p-value was less than 0.05. 
Results 
We identified 20 patients, 17 of whom were girls (85%) 
and the remaining 3, boys. Mean age at diagnosis was 6.5 ± 
1.8 years (range, 3 to 9 years). Thirteen patients were diag-
nosed with bilateral diseases (65%). The mean initial and worst 
visual acuity were both approximately 20 / 2000 (logarithm of 
the minimum angle of resolution [logMAR] scale, 1.89 ± 
0.91 and 1.91 ± 0.91, respectively). Sixteen patients (80%) 
exhibited visual acuity worse than 20 / 200. However, 16 pa-
tients (80%) recovered to a visual acuity level better than 20 
/ 40, and the mean final visual acuity was 20 / 25 (logMAR 
scale, 0.07 ± 0.10). The duration between the worst visual 
acuity and 20 / 40 was 2.30 ± 2.80 months (6 days to 8 months). 
The time between the worst visual acuity and final visual 
acuity was 5.51 ± 6.12 months (6 days to 22 months). Four 
patients showed no recovery of visual acuity, 3 patients Korean J Ophthalmol Vol.25, No.2, 2011
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Table 2. Clinical profiles of young children with optic neuritis
Characteristics    Data
Age (yr)     6.5 ± 1.82 (3-9)
Follow-up period (mon)   21.9 ± 20.3 (6-69)
Initial VA (logMAR)
*   1.89 ± 0.91 (0.40-3.50)
Worst VA (logMAR)
*   1.91 ± 0.91 (0.40-3.50)
VA better than 0.5 (% of eyes)        81.8
Duration between worst VA and 0.5 (mon)   2.30 ± 2.84 (0.2-8)
Recovery VA (logMAR)
*   0.07 ± 0.10 (-0.08-2.5)
Duration between worst VA and recovery VA (mon)   5.51 ± 6.12 (0.2-22)
Disc swelling (% of eyes)        75.8
Preceding febrile illness (% of patients)        40
Preceding vaccination (% of patients)        10
VA = visual acuity; logMAR = logarithm of the minimum angle of resolution.
*For statistical analysis, the visual acuities were transformed as follows: finger count to 2.5 logMAR, hand motion to 3 logMAR, and light 
perception to 3.5 logMAR visual acuities. 
showed bilateral disease, and 3 patients did not receive corti-
costeroid treatment. 
We administered a regimen of 10 to 30 milligrams of meth-
ylprednisolone per kilogram per day with 15 patients receiv-
ing this treatment. Based on previous reports of cortico-
steroid treatment on favorable visual outcomes in childhood 
optic neuritis, we recommended the treatment to every 
parent. However, 5 patients refused the therapy and under-
went a follow-up. Compared to the non-treated subjects, pa-
tients who received intravenous corticosteroid treatment re-
sulted in better visual outcomes (p = 0.043). There has been 
no complication regarding the treatment; the minimum age 
of the treated subjects was 3 years.  
Disc swelling was observed in 75.8% of eyes (25 eyes). 
Visual evoked potential test was performed in 13 patients, 
and all of them showed abnormal responses, reduced ampli-
tude, or delayed latency. Color vision tests were done on 12 
eligible patients. Ten patients did not even notice the demo 
plates, while the other 2 patients showed nonspecific 
red-green and mild red-green defects, respectively. Goldmann 
perimetry was conducted with the same 12 patients. Six of 
the patients experienced central and paracentral scotomas, 4 
patients reported diffuse decreased central sensitivity, 1 pa-
tient exhibited a paracentral island, and the other patient re-
ported no generalized depression.
Eight patients reported suffering from febrile illnesses be-
fore the onset of acute visual loss, and 2 patients had received 
the vaccine for measles, mumps, and rubella prior to the 
attack. 
With the exception of 2 patients, all children had a baseline 
brain MRI. Seven of the patients exhibited no abnormalities. 
There were 3 and 5 patients in this study who exhibited optic 
nerve enhancement and high signal lesions in the white mat-
ter, respectively. On the MRI of the other 3 patients, both 
high signals in the optic nerve and white matter lesions in the 
brain were observed. 
The mean follow-up period was 21.9 ± 20.3 months (range, 
6 to 69 months). During that time, five patients developed 
multiple sclerosis. Four of the patients were female, and 2 of 
them did not initially receive intravenous corticosteroid 
treatment for optic neuritis. We conducted a crossover tabu-
lation test for all discrete variables with the risk of MS: age at 
diagnosis, sex, corticosteroid treatment, febrile illness or 
vaccination, and brain white matter lesions on the MRI. Only 
the presence of MRI lesions in the brain was identified as a 
risk factor for MS (p = 0.008). The use of corticosteroid treat-
ment did not affect the risk of MS (Tables 1 and 2).
Discussion 
According to the ONTT, female predominance was ob-
served in adulthood optic neuritis, that is, 77% of the enrolled 
patients were female [16]. With regards to its dominance in 
childhood, there has been some controversy regarding a fe-
male predilection for the condition, and the ratio of females 
to males affected was 2:3 to 4:1 [2,6,7,17]. Some authors re-
ported that no sex preponderance was found in prepubescent 
children, but the female-to-male ratio increased to 2:1 after 
puberty [4,6,12]. In a previous study conducted in Thailand, 
the proportions of females were 59% and 71% of patients 
with optic neuritis age under 10 and between 10 and 12, re-
spectively [13]. However, in this study, a female predom-
inance was detected with 85% of the patients being female. 
Factors other than hormonal effects may be attributed to fe-
male preponderance, but they have yet to be discovered. 
Childhood optic neuritis was considered to be bilateral in 
nature. Contrary to the inclusion criteria of the ONTT, which 
covers only patients with unilateral visual acuity loss [16], 
some authors have recruited children with bilateral optic neu-
ritis [18], while other authors did not attempt to exclusively 
include bilateral diseases, but exclusively reported cases in 
which the conditions were bilateral [11,19]. There were 13 
cases of bilateral disease among our 20 patients, which was 
consistent with previous articles where bilateral disease was DH Jo, et al. Optic Neuritis in Korean Children
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reported in the range of 42% to 87% [2,6,20]. 
Initial profound visual loss occurred more commonly in 
children than adults. The authors reported that 84% to 100% 
of childhood patients experienced visual acuity of 20 / 200 or 
worse upon presentation [6,10]. According to the ONTT, ini-
tial visual acuity was better than 20 / 200 in 64.1% of the 454 
patients [21]. In our study, the mean initial visual acuity was 
about 20 / 2,000, and 80% of patients experienced visual 
acuity less than 20 / 200. Despite severe visual loss at the ini-
tial phase, visual prognosis was good to excellent in the 
childhood optic neuritis patients. Previous articles reported 
that 53% to 92% of patients recovered visual acuity better 
than 20 / 40 [2,12,17]. The ONTT provided long-term fol-
low-up results of visual prognosis: 72% of the affected eyes 
had a visual acuity of 20 / 20 or better, and 66% of patients 
had a visual acuity of 20 / 20 or better in both eyes at 
15-years’ follow-up [22]. In this study, with the exception of 
4 patients who exhibited no recovery of their visual acuity, 
the mean final visual acuity was approximately 20 / 25 in 16 
patients, all of whom showed a visual acuity better than 20 / 
40, the visual acuity which could be regarded as functionally 
sound. The durations between the worst visual acuity and 20 
/ 40 were 2.30 ± 2.80 months. 
This study was not a controlled study, and the number of 
study patients was small. However, we were able to identify 
significant beneficial effects of intravenous corticosteroid 
therapy on the visual outcomes. We employed the regimen of 
10 to 30 milligrams of methylprednisolone per kilogram per 
day, which was consistent with previous articles that reported 
satisfactory visual outcomes with corticosteroid therapy 
[2,4]. Of course, there have also been reports showing no cor-
relation between the use of steroids and the final visual out-
comes, making the decision of corticosteroid treatment on 
young children difficult and controversial [6,12]. However, it 
is both logical and ethical to treat optic neuritis patients with 
corticosteroids when taking the suspected autoimmune 
mechanism underlying the pathogenesis of optic neuritis into 
account [1].
Many reports have focused on the association between op-
tic neuritis and MS, because MS affects both the quality of 
life of the patients and the overall prognosis. According to 
the ONTT, the aggregate cumulative probabilities of devel-
oping MS were 30%, 38%, and 50% with 5-year, 10-year, 
and 15-year follow-ups, respectively [23]. In a study of child-
hood optic neuritis, Lucchinetti et al. [5] estimated the risk of 
MS to be 13%, 19%, 22%, and 26% after 10, 20, 30, and 40 
years from the onset of optic neuritis. In another case series, 
the risk of developing MS was estimated to be 8% to 50% 
[3,7-11]. Meadows [18] reported no cases of MS over a fol-
low-up period of 3 to 18 years. In our study, during the mean 
follow-up period of 21.9 ± 20.3 months, 5 patients (20%) 
were diagnosed with MS. After the ONTT reports, it became 
commonly accepted that steroid therapy did not alter the vis-
ual outcomes or the risk of MS in adults. In addition, we find 
no significance in corticosteroids preventing MS. Only the 
presence of MRI lesions, the most important risk factor in the 
ONTT, affected the risk of MS. In our study, only patients 
who showed abnormalities in the baseline MRI developed 
MS. This finding was comparable to the findings of the 
ONTT, which reported the risk of MS after 15 years increas-
ing 25% to 72% in cases where the baseline MRI showed one 
or more lesions [23], and the findings of the study on patients 
were younger than 18 years of age [24].
This study has the same disadvantage as other studies con-
cerning childhood optic neuritis: the study population is too 
small to fully analyze the prognosis depending on the treat-
ment and risk factors of multiple sclerosis. The prevalence of 
optic neuritis in children is known to be less than in adults, 
and thus the possibility of studying large population of pa-
tients is considered fairly low. Nevertheless, we found that 
steroid treatment exerted a significant effect on visual out-
comes, and the presence of MRI lesions had a statistically 
significant effect on the risk of MS.
Additionally, the patients in this study were all Koreans, 
and thus the differences between previous reports and this 
study might be based on the ethnic background. Some au-
thors have reported that the incidence of multiple sclerosis 
was low in cases of childhood optic neuritis among Asians 
[2,13]. However, this study recruited a large number of pa-
tients who were younger than 10 years when diagnosed with 
optic neuritis, and thus created a distinction between our re-
sults and the previous articles. Previous reports regarding 
childhood optic neuritis that studied such a broad age group 
or such a small study population exhibited insignificant 
results.
In this study, we demonstrated the clinical characteristics 
of optic neuritis in young children, reaffirmed some aspects 
of previous studies, and clarified the attributes of the specific 
age group under age 10. In particular, the patients in this age 
group tended to be female, have bilateral disease, and despite 
initial deep visual loss, recovered their visual acuity within a 
few months. Corticosteroid treatment appeared to exert a 
helpful effect on the visual outcomes, and in cases involving 
MRI lesions at baseline, the risk of developing MS tended to 
be higher. 
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